Clinical trials: Myelogenous Leukemia, Acute
Acute Myeloid Leukemia
Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
The purpose of this study in AML patients is to test whether vadastuximab talirine (SGN-CD33A; 33A) combined with either azacitidine or decitabine improves remission rates and extends overall survival as compared to placebo…
- Trial name
- CASCADE (NCT02785900)
- Testing
- 33A, azacitidine, decitabine
- Where
- 128 sites in United States, Australia and 14 more
- Volunteers
- 240 people
- Sponsor
- Seagen Inc.
Leukemia, Myeloid, Acute
Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Phase I, interventional, single-arm, open-label, treatment study to evaluate the safety and effectiveness of CD33-CLL1 CAR in patients with relapsed and/or refractory acute myeloid leukemia (AML).
- Trial name
- NCT05016063
- Testing
- Fludarabine, Cytoxan, Dual CD33-CLL1 CAR-T cells
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Xinqiao Hospital of Chongqing
Acute Myeloid Leukemia
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk…
- Trial name
- NCT05554393
- Testing
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 187 sites in United States, Canada and 1 more
- Volunteers
- 153 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia
Venetoclax With Hypomethylating Agents in Newly Diagnosed AML Unfit for Intensive Chemotherapy
This single-arm interventional study evaluated the short-term outcome of one 28-day cycle of venetoclax combined with a hypomethylating agent (azacitidine or decitabine) in adults with newly diagnosed acute myeloid leukemia who…
- Trial name
- NCT07773909
- Testing
- Venetoclax, Azacitidine, Decitabine
- Where
- Bangladesh
- Volunteers
- 24 people
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Chronic Myeloproliferative Disorders, Leukemia
Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant
RATIONALE: Studying immune response to flu vaccine in patients who have undergone a stem cell transplant may help doctors plan the best treatment.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00964821
- Testing
- trivalent influenza vaccine, Immunoenzyme technique, Laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 459 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Chronic Myeloid Leukemia
Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients
The aim of this phase I/II trial is to determine the dose of daunorubicine to be associated with cytarabine and Imatinib for induction therapy in patients with chronic myelogenous leukemia in myeloid acute phase.
- Trial name
- NCT00219765
- Testing
- Imatinib mesylate 600 mg, Cytarabine, Daunorubicine
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Poitiers University Hospital
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia
This clinical trial studies the side effects of gemtuzumab ozogamicin and how well it works in treating patients with acute myeloid leukemia.
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Trial name
- NCT01548911
- Testing
- gemtuzumab ozogamicin, laboratory biomarker analysis
- Sponsor
- Wake Forest University Health Sciences
Leukemia
A Randomized Phase III Study of Intensive Consolidation With High Dose Cytosine Arabinoside in Acute Myelogenous Leukemia (AML-8B)
RATIONALE: Patient abstract not available PURPOSE: Patient abstract not available
- Trial name
- NCT01324063
- Testing
- sargramostim, amsacrine, cytarabine
- Volunteers
- 160 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PSC 833 may increase the effectiveness of chemotherapy by making cancer cells more sensitive to the drugs.
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7)
- Trial name
- NCT00006363
- Testing
- cytarabine, daunorubicin hydrochloride, etoposide
- Where
- United States
- Volunteers
- 720 people
- Sponsor
- National Cancer Institute (NCI)
Myelodysplastic Syndromes (MDS), Acute Myeloid Leukaemia (AML)
A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia
Myelodysplastic Syndrome (MDS) is a disease of the bone marrow characterized by anemia,neutropenia, and thrombocytopenia (low red blood cell, white blood cell, and platelet counts).
- Trial name
- Aza-E (NCT01488565)
- Testing
- Azacitidine and eltrombopag
- Where
- 2 sites in Australia
- Volunteers
- 25 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study
This study evaluates how well the heart, lungs, and muscles are working individually, and how these systems are working together in transplant survivors.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma
- Trial name
- NCT04537871
- Testing
- Bioelectric Impedance Analysis, Biospecimen Collection, Cardiopulmonary Exercise Testing
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- City of Hope Medical Center
Leukemia
Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver tumor-killing substances to them, without harming normal cells.
- Trial name
- NCT00002609
- Testing
- lintuzumab, cytarabine, idarubicin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia
Biomarkers in Samples of Bone Marrow From Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01290107
- Testing
- DNA analysis, gene rearrangement analysis, microarray analysis
- Volunteers
- 9 people
- Sponsor
- Children's Oncology Group
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Busulfan and Cyclophosphamide Followed By ALLO BMT
This is a treatment guideline to allow routine clinical data to be collected and maintained in Oncore (clinical database) and the University of Minnesota Blood and Marrow Database as part of the historical database maintained by…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT01685411
- Testing
- Allopurinol, Keppra, Busulfan
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Relapsed or Refractory IDH1 Mutation-Positive Acute Myeloid Leukemia
A Clinical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia
This clinical trial is a multicenter, single-arm, open-label study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of olutasidenib administered orally twice daily under fasting conditions for one cycle of…
- Trial name
- NCT07604064
- Testing
- Olutasidenib
- Where
- Japan
- Volunteers
- 3 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia
This phase II trial studies how well vosaroxin and cytarabine work in treating patients with untreated acute myeloid leukemia. Drugs used in chemotherapy, such as vosaroxin and cytarabine, work in different ways to stop the…
- Conditions
- Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Multilineage Dysplasia, Myeloid Sarcoma
- Trial name
- VITAL (NCT02658487)
- Testing
- Cytarabine, Vosaroxin
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
AML, Acute Myeloid Leukemia
Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)
A primary goal of this clinical research study is to find the highest safe dose of sorafenib that can be given in combination with idarubicin and Ara-C for the treatment of acute myelogenous leukemia (AML) and high-risk…
- Conditions
- AML, Acute Myeloid Leukemia, Myelodysplastic Disorders
- Trial name
- NCT00542971
- Testing
- Idarubicin, Sorafenib, Ara-C
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed/Refractory Acute Myeloid Leukemia
Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia
This study will evaluate the safety and efficacy of NK520 in the treatment of relapsed/refractory acute myeloid leukemia. NK520 will be administered by intravenous injection.
- Trial name
- NCT06541444
- Testing
- NK520
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Base Therapeutics (Shanghai) Co., Ltd.
Leukemia, Myelodysplastic Syndromes
Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of dolastatin 10 in treating patients who have refractory…
- Trial name
- NCT00003693
- Testing
- Dolastatin 10
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Hodgkin's Lymphoma or Hodgkin's Disease, Acute Leukaemia
Palifermin After Haploidentical PBSCT
This is a double blind, placebo controlled clinical trial, where patients with an advanced form of blood cancer are treated with haploidentical allogeneic peripheral blood progenitor cell (PBPC) transplant after which they are…
- Conditions
- Non-Hodgkin's Lymphoma or Hodgkin's Disease, Acute Leukaemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia
- Trial name
- KGF Haplo Allo (NCT00570999)
- Testing
- Palifermin
- Where
- Germany
- Sponsor
- European Society for Blood and Marrow Transplantation